Massachusetts Financial Services Co. MA Has $109.28 Million Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Massachusetts Financial Services Co. MA lessened its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 22.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 817,804 shares of the life sciences company's stock after selling 238,368 shares during the quarter. Massachusetts Financial Services Co. MA owned about 0.52% of Illumina worth $109,283,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Scholtz & Company LLC purchased a new stake in shares of Illumina in the 4th quarter valued at $2,844,000. Groupama Asset Managment grew its position in shares of Illumina by 12.9% in the 4th quarter. Groupama Asset Managment now owns 5,082 shares of the life sciences company's stock valued at $679,000 after buying an additional 579 shares during the last quarter. Trexquant Investment LP increased its position in Illumina by 16.7% during the fourth quarter. Trexquant Investment LP now owns 142,977 shares of the life sciences company's stock worth $19,106,000 after buying an additional 20,506 shares during the period. HighPoint Advisor Group LLC increased its holdings in shares of Illumina by 15.9% in the 4th quarter. HighPoint Advisor Group LLC now owns 2,121 shares of the life sciences company's stock valued at $283,000 after acquiring an additional 291 shares during the period. Finally, Cannell & Spears LLC raised its position in Illumina by 3.9% in the 4th quarter. Cannell & Spears LLC now owns 664,473 shares of the life sciences company's stock valued at $88,794,000 after purchasing an additional 24,716 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Remove Ads

Illumina Price Performance

Shares of ILMN traded down $5.90 during mid-day trading on Thursday, hitting $70.40. The company's stock had a trading volume of 880,562 shares, compared to its average volume of 2,248,552. The firm has a 50-day moving average price of $90.77 and a 200 day moving average price of $123.08. The stock has a market capitalization of $11.15 billion, a price-to-earnings ratio of -9.16, a PEG ratio of 1.60 and a beta of 1.38. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, research analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ILMN. Citigroup dropped their price target on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a research note on Monday. Guggenheim reduced their price objective on shares of Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Canaccord Genuity Group dropped their target price on shares of Illumina from $135.00 to $115.00 and set a "hold" rating for the company in a report on Tuesday, March 11th. Hsbc Global Res lowered Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. Finally, Barclays decreased their target price on Illumina from $100.00 to $77.00 and set an "underweight" rating on the stock in a research report on Thursday. One analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $138.70.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.